Raltegravir-based HIV postexposure prophylaxis (PEP) in a real-life clinical setting: fewer drug–drug interactions (DDIs) with improved adherence and tolerability
Raltegravir-based HIV postexposure prophylaxis (PEP) in a real-life clinical setting: fewer drug–drug interactions (DDIs) with improved adherence and tolerability